Guangxi Wuzhou Zhongheng Group (600252.SH): Injection thrombin (freeze-dried) is expected to win the bid for the national centralized volume procurement of Chinese patent medicines.

Guangxi Wuzhou Zhongheng Group (600252.SH) announced that according to the National Traditional Chinese Medicine Joint Procurement Office, on December 30, 2024, the "National Traditional Chinese Medicine Purchasing Alliance Centralized Quantity Procurement Preliminary Selection Results Announcement" was published on the Hubei medical insurance service platform. The subsidiary company, Wuzhou Pharmaceutical Products, intends to be awarded the bid for the centralized quantity procurement of the injection Thrombocytopenia (freeze-dried). Wuzhou Pharmaceutical Products intend to be selected for the National Traditional Chinese Medicine Purchasing Alliance's centralized quantity procurement of the injection Thrombocytopenia (freeze-dried) (specifications 150mg per unit), with a total sales revenue of 6.70 billion yuan in the 2023 fiscal year, accounting for 21.63% of the company's total operating income of 30.97 billion yuan in 2023.